Showing 1 - 3 results of 3 for search 'Jeff P. Sharman', query time: 0.02s Refine Results
  1. 1
    Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results

    Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results by Mazyar Shadman, John M. Burke, Jennifer Cultrera, Habte A. Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators

    Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators by Tara Graff, Ian Flinn, Jeff P. Sharman, Steven Liu, Bertrand M. Anz, Mitul Gandhi, Ayed Ayed, Richard Zuniga, Abdul Hai Mansoor, Lourenia M. Cassoli, Mei Wu, Prachi Jani, Juliana M. L. Biondo, Tony Lin, John M. Burke

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

    Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study by Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, Saibah Chohan, Rucha Kothari, Connie Lee Batlevi, Jamie Hirata, Deniz Sahin, Calvin Lee, Matthew Sugidono, Hervé Tilly

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: